202 related articles for article (PubMed ID: 11695560)
1. P53+/- hemizygous knockout mouse: overview of available data.
Storer RD; French JE; Haseman J; Hajian G; LeGrand EK; Long GG; Mixson LA; Ochoa R; Sagartz JE; Soper KA
Toxicol Pathol; 2001; 29 Suppl():30-50. PubMed ID: 11695560
[TBL] [Abstract][Full Text] [Related]
2. CB6F1-rasH2 mouse: overview of available data.
Usui T; Mutai M; Hisada S; Takoaka M; Soper KA; McCullough B; Alden C
Toxicol Pathol; 2001; 29 Suppl():90-108. PubMed ID: 11695565
[TBL] [Abstract][Full Text] [Related]
3. Xpa and Xpa/p53+/- knockout mice: overview of available data.
van Kreijl CF; McAnulty PA; Beems RB; Vynckier A; van Steeg H; Fransson-Steen R; Alden CL; Forster R; van der Laan JW; Vandenberghe J
Toxicol Pathol; 2001; 29 Suppl():117-27. PubMed ID: 11695547
[TBL] [Abstract][Full Text] [Related]
4. Neonatal mouse model: review of methods and results.
McClain RM; Keller D; Casciano D; Fu P; MacDonald J; Popp J; Sagartz J
Toxicol Pathol; 2001; 29 Suppl():128-37. PubMed ID: 11695548
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.
Lina BA; Woutersen RA; Bruijntjes JP; van Benthem J; van den Berg JA; Monbaliu J; Thoolen BJ; Beems RB; van Kreijl CF
Toxicol Pathol; 2004; 32(2):192-201. PubMed ID: 15200157
[TBL] [Abstract][Full Text] [Related]
6. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
Cohen SM
Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of hormonal carcinogenesis in the p53+/- hemizygous knockout mouse: studies with diethylstilbestrol.
Carmichael PL; Mills JJ; Campbell M; Basu M; Caldwell J
Toxicol Pathol; 2001; 29 Suppl():155-60. PubMed ID: 11695552
[TBL] [Abstract][Full Text] [Related]
8. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
9. Oxymetholone: III. Evaluation in the p53+/- transgenic mouse model.
Stoll RE; Holden HE; Barthel CH; Blanchard KT
Toxicol Pathol; 1999; 27(5):513-8. PubMed ID: 10528630
[TBL] [Abstract][Full Text] [Related]
10. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
11. Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing.
Venkatachalam S; Tyner SD; Pickering CR; Boley S; Recio L; French JE; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():147-54. PubMed ID: 11695551
[TBL] [Abstract][Full Text] [Related]
12. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
13. A perspective on current and future uses of alternative models for carcinogenicity testing.
Goodman JI
Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
[TBL] [Abstract][Full Text] [Related]
14. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models.
van Steeg H; de Vries A; van Oostrom CTh ; van Benthem J; Beems RB; van Kreijl CF
Toxicol Pathol; 2001; 29 Suppl():109-16. PubMed ID: 11695546
[TBL] [Abstract][Full Text] [Related]
15. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
16. The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results.
Mauthe RJ; Gibson DP; Bunch RT; Custer L
Toxicol Pathol; 2001; 29 Suppl():138-46. PubMed ID: 11695550
[TBL] [Abstract][Full Text] [Related]
17. Detection of genotoxic and non-genotoxic carcinogens in Xpc(-/-)p53(+/-) mice.
Melis JP; Speksnijder EN; Kuiper RV; Salvatori DC; Schaap MM; Maas S; Robinson J; Verhoef A; van Benthem J; Luijten M; van Steeg H
Toxicol Appl Pharmacol; 2013 Jan; 266(2):289-97. PubMed ID: 23153559
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.
Petruska JM; Frank DW; Freeman GB; Evans EW; MacDonald JS
Toxicol Pathol; 2002; 30(6):696-704. PubMed ID: 12512871
[TBL] [Abstract][Full Text] [Related]
19. Use of DNA repair-deficient XPA transgenic mice in short-term carcinogenicity testing.
van Steeg H; Klein H; Beems RB; van Kreijl CF
Toxicol Pathol; 1998; 26(6):742-9. PubMed ID: 9864090
[TBL] [Abstract][Full Text] [Related]
20. The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis.
Tamaoki N
Toxicol Pathol; 2001; 29 Suppl():81-9. PubMed ID: 11695564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]